HS-110 for the Treatment of Non-small Cell Lung Cancer

HS-110 (viagenpumatucel-L) is our first biologic product candidate in a series of proprietary ImPACT® based immunotherapies designed to stimulate a patient’s own T-cells to destroy cancer.

Combination Therapies Indication Preclinical Phase 1 Phase 2 Phase 3 Market Comments


Preclinical Phase complete
Phase 1 Phase complete
Phase 2 Phase in progress
Phase 3 Phase not started
Market Phase not started
ImPACT® activation technology in combination with nivolumab and other checkpoint inhibitors TBA

Designed to Secrete a Wide Range of Lung Cancer-Associated Antigens

Using our ImPACT platform technology, Heat developed HS-110 as a treatment for patients with non-small cell lung cancer. HS-110 is made of a cancer cell line that has been genetically modified using our ImPACT technology platform. It is designed to secrete a wide range of lung cancer-associated antigens bound to gp96 proteins while activating a broad, T-cell mediated immune response against the patient’s cancer.

HS-110 Phase 2 Clinical Trial

Our HS-110 Phase 2, multicenter clinical trial is evaluating the safety and efficacy of HS-110 in combination with Bristol-Myers Squibb’s checkpoint inhibitor, nivolumab (Opdivo®), in patients with NSCLC whose cancers have progressed after first-line therapy. Positive interim results for the first 15 patients enrolled suggest HS-110 plays an integral role in tumor reduction and may enhance efficacy of checkpoint inhibitors in lung cancer patients.

Visit www.clinicaltrials.gov for more details.

A Phase 1b/2 Study of HS-110 in Combination with Multiple Treatment Regimens in Patients with NSCLC


HS-110 Product Manufacturing

The HS-110 product used in our clinical trials is manufactured under cGMP guidelines. The cell line is grown in large quantities, dispensed into individual doses, frozen in liquid nitrogen, irradiated to render cell replication incompetent and quality tested in compliance with FDA guidelines.